Respiratory Syncytial Virus (RSV)
Prevalence
>33,000,000 cases across the globe
Currently, there are no safe and effective treatments that exist for RSV infection
>3,000,000 hospitalizations in children under 5
>177,000 hospitalizations in adults over 65 years
RSV Complications & Death
Approximately 3 million children are hospitalized and there are more than 100,000 deaths each year from complications associated with RSV.
Across the U.S., there are 2.1 million hospitalizations and outpatient visits in children under 5 years of age.
For adults 65 years and older, RSV results in more than 177,000 hospitalizations and 14,000 deaths annually in the U.S.
Inhalon’s Solution
Using its patented drug delivery platform, Inhalon’s direct inhaled delivery of IN-002 into the lung promises to be significantly more effective for combating RSV infections. Patients may benefit from swift recovery of symptoms with rapid control of inflammation. For infants and young children suffering from RSV, Inhalon’s precedent-setting inhaled dosing offers greater comfort and ease, with the potential to shift care to an at home “test-and-treat” product.
1
2
3
-
Li, You et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.” Lancet (London, England) vol. 399,10340 (2022): 2047-2064. doi:10.1016/S0140-6736(22)00478-0
-
Red Book: 2021 Report of the Committee on Infectious Diseases, 32nd Edition. Editor: David W. Kimberlin
-
Hall, Caroline Breese et al. “The Burden of Respiratory Syncytial Virus Infection in Young Children.” The New England Journal of Medicine vol. 360,6 (2009): 588-98. doi:10.1056/NEJMoa0804877
SARS-CoV-2
Severe acute respiratory syndrome (SARS) is viral respiratory disease caused by coronavirus. In 2002-2003, approximately 800 people died from SARS-CoV-1. In 2019, another corona virus strain, SARS-CoV-2, caused the COVID-19 pandemic. Inhalon, funded by the US Military, is working on an inhaled antibody treatment that would treat all versions of SARS virus (pan-SARS). Currently, Inhalon is testing an anti-SARS-CoV-2 antibody in the clinic.
Human Metapneumovirus (hMPV)
Prevalence in the US Alone
>1,000,000 outpatient clinic visits
Currently there is no vaccine or specific antiviral treatment available for hMPV
>260,000 severe cases resulting in Emergency Department visits among US children under the age of 5
>20,000 hospitalizations
hMPV Illness & Death in Children
hMPV represents one of the leading causes of acute respiratory tract infections in children, immune-compromised patients and the elderly and is considered a primary cause of death in infants under five years of age. Symptoms associated with hMPV are mainly respiratory problems ranging from coughing, wheezing, and fever to more severe complications, such as pneumonia. Several studies have shown that hMPV is prevalent worldwide, affecting up to 86% of the global population of infants under five years old.
hMPV is a member of the paramyxovirus family, like respiratory syncytial virus (RSV). Use of molecular diagnostic testing has increased identification of hMPV as a significant cause of upper and lower respiratory infection.
Inhalon’s Solution
As with RSV, direct inhaled delivery of IN-003 into the lung promises to be significantly more effective for combating hMPV infections. Patients may benefit from swift recovery of symptoms with rapid control of inflammation. For infants and young children suffering from hMPV, Inhalon’s precedent-setting inhaled dosing offers greater comfort and ease, with the potential to shift care to an at home “test-and-treat” product.
1
2
1
-
Gálvez, Nicolás M S et al. “Host Components That Modulate the Disease Caused by hMPV.” Viruses vol. 13,3 519. 22 Mar. 2021, doi:10.3390/v13030519